Safety study of BSB-2002 for relapsed or refractory AML with NPM1 mutation
Part of Blood & lymphatic, Cancer clinical trials.
This is a Phase 1 trial testing a new drug called BSB-2002 in patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatments. The drug is designed specifically for patients whose cancer cells have a particular genetic change (NPM1 mutation) and may help control the cancer by activating the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You have AML (blood cancer) that has either relapsed (came back after remission) or is refractory (didn't respond to treatment), and you've received at least two prior treatment regimens
- Your cancer must carry a specific NPM1 genetic mutation (type A, D, G, or H) and you must be positive for a blood protein called HLA-A*02:01
- Your blast count (immature cancer cells in blood) must be manageable (below 20,000/μl), though hydroxyurea can help control this
- You have adequate veins for apheresis (a procedure to collect cells), or you're willing to have a central line placed for this purpose
- You're able and willing to follow all study requirements and give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This trial tests a new cell therapy (BSB-1001) given after a stem cell transplant to prevent or treat high-risk blood cancers like AML, ALL, or MDS. It is for patients with a specific genetic marker and a matched donor.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This study tests BSB-2002, a new type of immune cell therapy, in patients whose acute myeloid leukemia (AML) has come back or hasn't responded to prior treatments. The therapy uses the patient's own immune cells, modified in the lab to recognize and attack leukemia cells with a specific genetic mutation (NPM1).
This trial tests a new type of cell therapy, called MB-dNPM1-TCR.1, for people with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The therapy uses your own immune cells, which are specially trained to find and attack leukemia cells that have a specific mutation in the NPM1 gene.
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
Hear when a new AML With Mutated NPM1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.